A news item in the May 23, 2002, issue of BioWorld Today may have been unclear because of misplaced commas. Agreements Micrologix Biotech Inc. made include a combination of up-front and near-term cash and equity components totaling $800,000, cash and/or equity payable and valued at specified milestones totaling up to $4.35 million for both programs, and a royalty on product sales.

Editor's Note: The changes have been made on BioWorld Online.

No Comments